MicroRNA in radiotherapy: MiRage or miRador?

British Journal of Cancer

Volumn 112, Issue 5, 2015, Pages 777-782

  Korpela, E ^a,b   Vesprini, D ^a,b,c   Liu, S K ^a,b,c  

^a Canada   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

CANCER CONTROL; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; DNA DAMAGE; HUMAN; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY; REVIEW; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; DNA REPAIR; GENETICS; METABOLISM; NEOPLASMS; RADIATION DOSE;

DNA DAMAGE; DNA REPAIR; HUMANS; INDIVIDUALIZED MEDICINE; MICRORNAS; NEOPLASMS; RADIATION TOLERANCE; TUMOR MICROENVIRONMENT;

EID: 84928706853     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.6     Document Type: Review

References (51)

1. Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Cavalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, Hoebers F, Rietbergen MM, Leemans CR, Dekker A, Quackenbush J, Gillies RJ, Lambin P (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5: 4006.
2. Ameres SL, Zamore PD (2013) Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol 14(8): 475-488.
3. Arora H, Qureshi R, Jin S, Park A-K, Park W-Y (2011) miR-9 and let-7 g enhance the sensitivity to ionizing radiation by suppression of NF[kappa]B1. Exp Mol Med 43: 298-304.
4. Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ (2012) Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci USA 109(26): E1695-E1704.
5. Barnett GC, West CM, Dunning AM, Elliott RM, Coles CE, Pharoah PD, Burnet NG (2009) Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 9(2): 134-142.
6. Begg AC, Stewart FA, Vens C (2011) Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 11(4): 239-253.
7. Bentzen SM, Parliament M, Deasy JO, Dicker A, Curran WJ, Williams JP, Rosenstein BS (2010) Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. Int J Radiat Oncol Biol Phys 76(3 Suppl): S145-S150.
8. Bi N, Schipper MJ, Stanton P, Wang W, Kong F-M (2013) Serum miRNA signature to identify a patient's resistance to high-dose radiation therapy for unresectable non-small cell lung cancer. J Clin Oncol 31(Suppl): abstr 7580.
9. Bristow RG, Berlin A, Dal Pra A (2014) An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy. Br J Radiol 87(1035): 20130753.
10. Bussink J, Kaanders JH, van der Graaf WT, Oyen WJ (2011) PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol 8(4): 233-242.
11. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11): 857-866.
12. Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, Saltzman WM, Slack FJ (2015) MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518(7537): 107-110.
13. Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, Komaki R, Giri DK, Quini CC, Wolfe T, Peltier HJ, Bader AG, Heymach JV, Meyn RE, Welsh JW (2014) Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther 22(8): 1494-1503.
14. Drebber U, Lay M, Wedemeyer I, Vallbohmer D, Bollschweiler E, Brabender J, Monig SP, Holscher AH, Dienes HP, Odenthal M (2011) Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int J Oncol 39(2): 409-415.
15. Feng Z, Zhang C, Wu R, Hu W (2011) Tumor suppressor p53 meets microRNAs. J Mol Cell Biol 3(1): 44-50.
16. Francia S, Michelini F, Saxena A, Tang D, de Hoon M, Anelli V, Mione M, Carninci P, d/'Adda di Fagagna F (2012) Site-specific DICER and DROSHA RNA products control the DNA-damage response. Nature 488(7410): 231-235.
17. Grosso S, Doyen J, Parks SK, Bertero T, Paye A, Cardinaud B, Gounon P, Lacas-Gervais S, Noel A, Pouyssegur J, Barbry P, Mazure NM, Mari B (2013) MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis 4: e544.
18. Hall JS, Taylor J, Valentine HR, Irlam JJ, Eustace A, Hoskin PJ, Miller CJ, West CM (2012) Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. Br J Cancer 107(4): 684-694.
19. Hamama S, Noman MZ, Gervaz P, Delanian S, Vozenin MC (2014) MiR-210: A potential therapeutic target against radiation-induced enteropathy. Radiother Oncol 111(2): 219-221.
20. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ (2007) A microRNA component of the p53 tumour suppressor network. Nature 447(7148): 1130-1134.
21. Ho JJ, Metcalf JL, Yan MS, Turgeon PJ, Wang JJ, Chalsev M, Petruzziello-Pellegrini TN, Tsui AK, He JZ, Dhamko H, Man HS, Robb GB, Teh BT, Ohh M, Marsden PA (2012) Functional importance of Dicer protein in the adaptive cellular response to hypoxia. J Biol Chem 287(34): 29003-29020.
22. Hu H, Du L, Nagabayashi G, Seeger RC, Gatti RA (2010) ATM is down-regulated by N-Myc-regulated microRNA-421. Proc Natl Acad Sci USA 107(4): 1506-1511.
23. Huang S, Guo W, Tang Y, Ren D, Zou X, Peng X (2012) miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncol Rep 28(5): 1831-1837.
24. Huang X, Taeb S, Jahangiri S, Emmenegger U, Tran E, Bruce J, Mesci A, Korpela E, Vesprini D, Wong CS, Bristow RG, Liu FF, Liu SK (2013) miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res 73(23): 6972-6986.
25. Jacob NK, Cooley JV, Yee TN, Jacob J, Alder H, Wickramasinghe P, Maclean KH, Chakravarti A (2013) Identification of sensitive serum microRNA biomarkers for radiation biodosimetry. PLoS One 8(2): e57603.
26. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368(18): 1685-1694.
27. Ke G, Liang L, Yang JM, Huang X, Han D, Huang S, Zhao Y, Zha R, He X, Wu X (2013) MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene. Oncogene 32(25): 3019-3027.
28. Klotz L, Vesprini D, Sethukavalan P, Jethava V, Zhang L, Jain S, Yamamoto T, Mamedov A, Loblaw A (2014) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol. e-pub ahead of print 15 December 2014.
29. Korpela E, Vesprini D, Liu SK (2014) Endothelial perturbations and therapeutic strategies in normal tissue radiation damage. Radiat Oncol 9(1): 266.
30. Kraemer A, Anastasov N, Angermeier M, Winkler K, Atkinson MJ, Moertl S (2011) MicroRNA-mediated processes are essential for the cellular radiation response. Radiat Res 176(5): 575-586.
31. Lal A, Pan Y, Navarro F, Dykxhoorn DM, Moreau L, Meire E, Bentwich Z, Lieberman J, Chowdhury D (2009) miR-24-mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat Struct Mol Biol 16(5): 492-498.
32. Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, Berlin A, Have CL, Ramnarine VR, Yao CQ, Malloff CA, Lam LL, Xie H, Harding NJ, Mak DY, Chu KC, Chong LC, Sendorek DH, P'ng C, Collins CC, Squire JA, Jurisica I, Cooper C, Eeles R, Pintilie M, Dal Pra A, Davicioni E, Lam WL, Milosevic M, Neal DE, van der Kwast T, Boutros PC, Bristow RG (2014) Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol 15(13): 1521-1532.
33. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, Wiggins JF, Bader AG, Fagin R, Brown D, Tang DG (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17(2): 211-215.
34. Meijer TW, Kaanders JH, Span PN, Bussink J (2012) Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 18(20): 5585-5594.
35. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133(2): 647-658.
36. Metheetrairut C, Slack FJ (2013) MicroRNAs in the ionizing radiation response and in radiotherapy. Curr Opin Genet Dev 23(1): 12-19.
37. Moskwa P, Buffa FM, Pan Y, Panchakshari R, Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K, Weinstock DM, Gorospe M, Harris AL, Helleday T, Chowdhury D (2011) miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 41(2): 210-220.
38. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, deVere White RW, Kung HJ, Evans CP, Gao AC (2012) MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One 7(3): e32832.
39. Pajonk F, Vlashi E, McBride WH (2010) Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 28(4): 639-648.
40. Palayoor ST, John-Aryankalayil M, Makinde AY, Falduto MT, Magnuson SR, Coleman CN (2014) Differential expression of stress and immune response pathway transcripts and miRNAs in normal human endothelial cells subjected to fractionated or single-dose radiation. Mol Cancer Res 12(7): 1002-1015.
41. Schwarzenbach H, Nishida N, Calin GA, Pantel K (2014) Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 11(3): 145-156.
42. Simone BA, Ly D, Savage JE, Hewitt SM, Dan TD, Ylaya K, Shankavaram U, Lim M, Jin L, Camphausen K, Mitchell JB, Simone NL (2014) microRNA alterations driving acute and late stages of radiation-induced fibrosis in a murine skin model. Int J Radiat Oncol Biol Phys 90(1): 44-52.
43. Stewart FA, Seemann I, Hoving S, Russell NS (2013) Understanding radiation-induced cardiovascular damage and strategies for intervention. Clin Oncol (R Coll Radiol) 25(10): 617-624.
44. Surova O, Akbar NS, Zhivotovsky B (2012) Knock-down of core proteins regulating microRNA biogenesis has no effect on sensitivity of lung cancer cells to ionizing radiation. PLoS One 7(3): e33134.
45. Vesprini D, Liu S, Nam R (2013) Predicting high risk disease using serum and DNA biomarkers. Curr Opin Urol 23(3): 252-260.
46. Wang SY, Shiboski S, Belair CD, Cooperberg MR, Simko JP, Stoppler H, Cowan J, Carroll PR, Blelloch R (2014) miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One 9(6): e98597.
47. Wang XC, Du LQ, Tian LL, Wu HL, Jiang XY, Zhang H, Li DG, Wang YY, Wu HY, She Y, Liu QF, Fan FY, Meng AM (2011) Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer 72(1): 92-99.
48. Weigel C, Schmezer P, Plass C, Popanda O (2014) Epigenetics in radiation-induced fibrosis. Oncogene. e-pub ahead of print 9 June 2014; doi:10.1038/onc.2014.145.
49. Xu N, Papagiannakopoulos T, Pan G, Thomson JA, Kosik KS (2009) MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. Cell 137(4): 647-658.
50. Yan D, Ng WL, Zhang X, Wang P, Zhang Z, Mo YY, Mao H, Hao C, Olson JJ, Curran WJ, Wang Y (2010) Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One 5(7): e11397.
51. Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, Park J, Shippy A (2008) Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71(4): 1028-1033.